Loss-of-function mutations of the MECP2 gene are the cause of most cases of Rett syndrome in females, a progressive neurodevelopmental disorder characterized by severe mental retardation, global regression, hand stereotypies, and microcephaly. On the other hand, gain of dosage of this gene causes the MECP2 duplication syndrome in males characterized by severe mental retardation, absence of speech development, infantile hypotonia, progressive spasticity, recurrent infections, and facial dysmorphism. Female carriers of a heterozygous duplication show a skewed X-inactivation pattern which is the most probable cause of the lack of clinical symptoms. In this paper, we describe a girl with a complex de novo copy number gain at Xq28 and non-skewed X-inactivation pattern that causes mental retardation and motor and language delay. This rearrangement implies triplication of the MECP2 and IRAK1 genes, but it does not span other proximal genes located in the common minimal region of patients affected by the MECP2 duplication syndrome. We conclude that the triplication leads to a severe phenotype due to random X-inactivation, while the preferential X chromosome inactivation in healthy carriers may be caused by a negative selection effect of the duplication on some proximal genes like ARD1A or HCFC1.

Keywords:
Array CGH, MECP2 duplication syndrome, Mental retardation, Rett syndrome, Xq28 triplication
1.
Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW: Methylation of Hpa II and Hha I sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet 51:1229–1239 (1992).
2.
Auber B, Burfeind P, Thiels C, Alsat EA, Shoukier M, et al: An unbalanced translocation resulting in a duplication of Xq28 causes a Rett syndrome-like phenotype in a female patient. Clin Genet 77:593–597 (2010).
3.
Bauters M, Van Esch H, Friez MJ, Boespflug-Tanguy O, Zenker M, et al: Nonrecurrent MECP2 duplications mediated by genomic architecture-driven DNA breaks and break-induced replication repair. Genome Res 18:847–858 (2008).
4.
Bialer MG, Anguiano A, Taff I, Shanmugham A, Lagrave D, White BJ: De novo trisomy Xq28-qter detected by subtelomeric FISH screening. Am J Hum Genet 73:300 (2003).
5.
Clayton-Smith J, Walters S, Hobson E, Burkitt-Wright E, Smith R, et al: Xq28 duplication presenting with intestinal and bladder dysfunction and a distinctive facial appearance. Eur J Hum Genet 17:434–443 (2009).
6.
de Brouwer AP, Yntema HG, Kleefstra T, Lugtenberg D, Oudakker AR, et al: Mutation frequencies of X-linked mental retardation genes in families from the EuroMRX consortium. Hum Mutat 28:207–208 (2007).
7.
del Gaudio D, Fang P, Scaglia F, Ward PA, Craigen WJ, et al: Increased MECP2 gene copy number as the result of genomic duplication in neurodevelopmentally delayed males. Genet Med 8:784–792 (2006).
8.
Echenne B, Roubertie A, Lugtenberg D, Kleefstra T, Hamel BC, et al: Neurologic aspects of MECP2 gene duplication in male patients. Pediatr Neurol 41:187–191 (2009).
9.
Friez MJ, Jones JR, Clarkson K, Lubs H, Abuelo D, et al: Recurrent infections, hypotonia, and mental retardation caused by duplication of MECP2 and adjacent region in Xq28. Pediatrics 118:e1687–1695 (2006).
10.
Froyen G, Van Esch H, Bauters M, Hollanders K, Frints SG, et al: Detection of genomic copy number changes in patients with idiopathic mental retardation by high-resolution X-array-CGH: important role for increased gene dosage of XLMR genes. Hum Mutat 28(10):1034–42 (2007).
11.
Grasshoff U, Bonin M, Goehring I, Ekici A, Dufke A, et al: De novo MECP2 duplication in two females with random X-inactivation and moderate mental retardation. Eur J Hum Genet 19:507–512 (2011).
12.
Hagberg B, Aicardi J, Dias K, Ramos O: A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett’s syndrome: report of 35 cases. Ann Neurol 14:471–479 (1983).
13.
Jeppesen P, Turner BM: The inactive X chromosome in female mammals is distinguished by a lack of histone H4 acetylation, a cytogenetic marker for gene expression. Cell 74:281–289 (1993).
14.
Kirk EP, Malaty-Brevaud V, Martini N, Lacoste C, Levy N, et al: The clinical variability of the MECP2 duplication syndrome: description of two families with duplications excluding L1CAM and FLNA. Clin Genet 75:301–303 (2009).
15.
Kishi N, Macklis JD: MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions. Mol Cell Neurosci 27:306–321 (2004).
16.
Lachlan KL, Collinson MN, Sandford RO, van Zyl B, Jacobs PA, Thomas NS: Functional disomy resulting from duplications of distal Xq in four unrelated patients. Hum Genet 115:399–408 (2004).
17.
Lammer EJ, Punglia DR, Fuchs AE, Rowe AG, Cotter PD: Inherited duplication of Xq27.2→qter: phenocopy of infantile Prader-Willi syndrome. Clin Dysmorphol 10:141–144 (2001).
18.
Lugtenberg D, Kleefstra T, Oudakker AR, Nillesen WM, Yntema HG, et al: Structural variation in Xq28: MECP2 duplications in 1% of patients with unexplained XLMR and in 2% of male patients with severe encephalopathy. Eur J Hum Genet 17:444–453 (2009).
19.
Makrythanasis P, Moix I, Gimelli S, Fluss J, Aliferis K, et al: De novo duplication of MECP2 in a girl with mental retardation and no obvious dysmorphic features. Clin Genet 78:175–180 (2010).
20.
Martínez F, León AM, Monfort S, Oltra S, Roselló M, Orellana M: Robust, easy, and dose-sensitive methylation test for the diagnosis of Prader–Willi and Angelman syndromes. Genetic Testing 10:174–177 (2006).
21.
Mnatzakanian GN, Lohi H, Munteanu I, Alfred SE, Yamada T, et al: A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nature Genet 36:339–341 (2004).
22.
Monfort S, Orellana C, Oltra S, Roselló M, Guitart M, Martínez F: Evaluation of MLPA for the detection of cryptic subtelomeric rearrangements. J Lab Clin Med 147:295–300 (2006).
23.
Moog U, Smeets EE, van Roozendaal KE, Schoenmakers S, Herbergs J, et al: Neurodevelopmental disorders in males related to the gene causing Rett syndrome in females (MECP2). Europ J Paediat Neurol 7:5–12 (2003).
24.
Muscatelli F, Verna JM, Philip N, Moncla A, Mattei MG, et al: Physical mapping of an Xq-proximal interstitial duplication in a male. Hum Genet 88:691–694 (1992).
25.
Novelli A, Bernardini L, Salpietro DC, Briuglia S, Merlino MV, et al: Disomy of distal Xq in males: case report and overview. Am J Med Genet A 128A:165–169 (2004).
26.
Reardon W, Donoghue V, Murphy AM, King MD, Mayne PD, et al: Progressive cerebellar degenerative changes in the severe mental retardation syndrome caused by duplication of MECP2 and adjacent loci on Xq28. Eur J Pediatr 169:941–949 (2010).
27.
Rett A: Über ein eigenartiges hirnatrophisches Syndrom bei Hyperammonämie im Kindesalter. Wien Med Wochenschr 116:723–726 (1966).
28.
Sánchez-Puig N, Fersht AR: Characterization of the native and fibrillar conformation of the human Nalpha-acetyltransferase ARD1. Protein Sci 15:1968–1976 (2006).
29.
Sanlaville D, Prieur M, de Blois MC, Genevieve D, Lapierre JM, et al: Functional disomy of the Xq28 chromosome region. Eur J Hum Genet 13:579–585 (2005).
30.
Sanlaville D, Schluth-Bolard C, Turleau C: Distal Xq duplication and functional Xq disomy. Orphanet J Rare Dis 4:4 (2009).
31.
Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY: Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum Mol Genet 11:115–124 (2002).
32.
Smyk M, Obersztyn E, Nowakowska B, Nawara M, Cheung SW, et al: Different-sized duplications of Xq28, including MECP2, in three males with mental retardation, absent or delayed speech, and recurrent infections. Am J Med Genet B Neuropsychiatr Genet 147B:799–806 (2008).
33.
Stankiewicz P, Lupski JR: Genome architecture, rearrangements and genomic disorders. Trends Genet 18:74–82 (2002).
34.
Sugiura N, Adams S M, Corriveau RA: An evolutionarily conserved N-terminal acetyltransferase complex associated with neuronal development. J Biol Chem 278:40113–40120 (2003).
35.
Trask BJ: Fluorescence in situ hybridization: applications in cytogenetics and gene mapping. Trends Genet 7:149–154 (1991).
36.
Vandewalle J, Van Esch H, Govaerts K, Verbeeck J, Zweier C, et al: Dosage-dependent severity of the phenotype in patients with mental retardation due to a recurrent copy-number gain at Xq28 mediated by an unusual recombination. Am J Hum Genet 85:809–822 (2009).
37.
Van Esch H, Bauters M, Ignatius J, Jansen M, Raynaud M, et al: Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males. Am J Hum Genet 77:442–453 (2005).
38.
Villard L: MECP2 mutations in males. J Med Genet 44:417–423 (2007).
39.
Wilson AC, Parrish JE, Massa HF, Nelson DL, Trask BJ, Herr W: The gene encoding the VP16-accessory protein HCF (HCFC1) resides in human Xq28 and is highly expressed in fetal tissues and the adult kidney. Genomics 25:462–468 (1995).
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.